Clinical trials: Community-Acquired Infection
Community-acquired Pneumonia
Safety and Efficacy of AON-D21 in Severe Community-Acquired Pneumonia.
The goal of this clinical trial is to compare the safety and efficacy of AON-D21 versus placebo, both on top of standard of care, in patients with severe community acquired pneumonia admitted to ICU (or similar unit).
- Trial name
- NCT05962606
- Testing
- AON-D21
- Where
- 27 sites in United States, Belgium and 4 more
- Volunteers
- 150 people
- Sponsor
- Aptarion Biotech AG
Community Acquired Pneumonia
Epidemiological Study on Community Acquired Pneumonia
The main objective of this study is to investigate prevalence and risk factors for community-acquired pneumonia (CAP) and its interaction with comorbidities in an unselected group of adult patients receiving outpatient and…
- Trial name
- CAPNETZ (NCT02139163)
- Where
- Germany
- Volunteers
- 20,000 people
- Sponsor
- Capnetz Stiftung
Community-acquired Pneumonia
Clinical Characteristics and Microbiology of Community-Acquired Pneumonia
Community-Acquired Pneumonia has become common. Additionally, the mortality is high. But the epidemiology of pathogen is various in different areas, which is crucial for the key treatment.
- Trial name
- NCT03098914
- Testing
- Cohort Study； pathogen； clinical features
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Beijing Haidian Hospital
Pneumonia, Pediatric Respiratory Diseases
Procalcitonin to Reduce Antibiotic Use in Pediatric Pneumonia
This pilot study will evaluate study processes and feasibility of a future large-scale clinical trial that proposes to test whether low-risk children managed as outpatients with community-acquired pneumonia (CAP) and…
- Conditions
- Pneumonia, Pediatric Respiratory Diseases, Antibiotic Use, Community-acquired Pneumonia
- Trial name
- PRAPP (NCT04963764)
- Testing
- Amoxicillin
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
Influenza, Community-acquired Pneumonia
Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years
This study will evaluate the relative vaccine effectiveness of quadrivalent adjuvanted inactivated influenza vaccine (aIIV4) versus quadrivalent high-dose inactivated influenza vaccine (HD-IIV4) in preventing polymerase chain…
- Conditions
- Influenza, Community-acquired Pneumonia, Cardiovascular Events
- Trial name
- NCT06029933
- Testing
- Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aIIV4), High-Dose Quadrivalent Inactivated Influenza Vaccine (HD-IIV4)
- Where
- United States
- Volunteers
- 1,500,000 people, healthy volunteers welcome
- Sponsor
- Kaiser Permanente
Community-acquired Pneumonia
Use of Non Steroidal Antiinflammatory Drugs in Patients With Community Acquired Pneumonia
To investigate exposure to nonsteroidal antiinflammatory drugs (NSAIDs) during outpatient management at the early stage of community-acquired pneumonia (CAP) requiring hospital consultation. Non-interventional observational study.
- Trial name
- ALPAJ (NCT02523885)
- Where
- 4 sites in France
- Volunteers
- 181 people
- Sponsor
- Hôpital Louis Mourier
Community-acquired Pneumonia
Phase II Clinical Study to Assess the Efficacy and Safety of Nemonoxacin Malate in Treating Adult Patients With Community-acquired Pneumonia (CAP)
The purpose of this study is to evaluate the safety, tolerability and population pharmacokinetics of oral nemonoxacin in community-acquired pneumonia (CAP) subjects.
- Trial name
- NCT01537250
- Testing
- Nemonoxacin 3 tablets
- Where
- 32 sites in China
- Volunteers
- 192 people
- Sponsor
- TaiGen Biotechnology Co., Ltd.
Community-Acquired Bacterial Pneumonia (CABP)
Safety and Efficacy Study of Ceftaroline in Elderly Subjects With Community-Acquired Bacterial Pneumonia
The purpose of this study is to determine the safety and efficacy of ceftaroline fosamil in elderly subjects with community-acquired bacterial pneumonia (CABP) receiving antibiotic therapy in the hospital.
- Trial name
- NCT01666743
- Testing
- Ceftaroline fosamil
- Sponsor
- Forest Laboratories